Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Vandercam

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Journal of the International AIDS Society|November 14, 2014
Factors associated with the continuum of care of HIV-infected patients in BelgiumDominique Van Beckhoven, Patrick Lacor, Michel Moutschen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2022
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of CancerJohan Maertens, Tom Lodewyck, J Peter Donnelly, et al.
AIDS Research and Human Retroviruses|March 11, 2008
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006Jurgen Vercauteren, Inge Derdelinckx, André Sasse, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Journal of the International AIDS Society|November 14, 2014
Factors associated with the continuum of care of HIV-infected patients in BelgiumDominique Van Beckhoven, Patrick Lacor, Michel Moutschen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2022
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of CancerJohan Maertens, Tom Lodewyck, J Peter Donnelly, et al.
AIDS Research and Human Retroviruses|March 11, 2008
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006Jurgen Vercauteren, Inge Derdelinckx, André Sasse, et al.
Pageof 4